Review article · 2020 · Open access

Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy

Alexandra E. Oxford, Erica S. Stewart, Troy T. Rohn

International Journal of Alzheimer s Disease, 2020, 1–13 · Published 1 April 2020 · DOI 10.1155/2020/5380346

Open PDFView at the publisherCite this paper

In brief

“Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy” is a 2020 review article by Alexandra E. Oxford and 2 co-authors, published in International Journal of Alzheimer s Disease. OpenAlex counts 123 citations as of 20 November 2026, which puts it in the top 2% of works published in 2020 by citations. It is open access under a CC BY licence: the full text is free to read at International Journal of Alzheimer s Disease.

Citations
123
Most cited in
2022 (35)
Field-weighted impact
2.40
References
103
Authors
3

Abstract

Human clinical trials seek to ameliorate the disease states and symptomatic progression of illnesses that, as of yet, are largely untreatable according to clinical standards. Ideally, clinical trials test “disease-modifying drugs,” i.e., therapeutic agents that specifically modify pathological features or molecular bases of the disease and would presumably have a large impact on disease progression. In the case of Alzheimer’s disease (AD), however, this approach appears to have stalled progress in the successful development of clinically useful therapies. For the last 25 years, clinical trials involving AD have centered on beta-amyloid (Aβ) and the Aβhypothesis of AD progression and pathology. According to this hypothesis, the progression of AD begins following an accumulation of Aβpeptide, leading to eventual synapse loss and neuronal cell death: the true overriding pathological feature of AD. Clinical trials arising from the Aβhypothesis target causal steps in the pathway in order to reduce the formation of Aβor enhance clearance, and though agents have been successful in this aim, they remain unsuccessful in rescuing cognitive function or slowing cognitive decline. As such, further use of resources in the development of treatment options for AD that target Aβ, its precursors, or its products should be reevaluated. The purpose of this review was to give an overview of how human clinical trials are conducted in the USA and to assess the results of recent failed trials involving AD, the majority of which were based on the Aβhypothesis. Based on these current findings, it is suggested that lowering Aβis an unproven strategy, and it may be time to refocus on other targets for the treatment of this disease including pathological forms of tau.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020). Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy. International Journal of Alzheimer s Disease, 2020, 1–13. https://doi.org/10.1155/2020/5380346

MLA 9

Oxford, Alexandra E., et al. “Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy.” International Journal of Alzheimer s Disease, vol. 2020, 2020, pp. 1–13. https://doi.org/10.1155/2020/5380346.

Chicago

Oxford, Alexandra E., Erica S. Stewart, and Troy T. Rohn. 2020. “Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy.” International Journal of Alzheimer s Disease 2020: 1–13. https://doi.org/10.1155/2020/5380346.

Harvard

Oxford, A. E., Stewart, E. S. and Rohn, T. T. (2020) ‘Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy’, International Journal of Alzheimer s Disease, 2020, pp. 1–13. doi:10.1155/2020/5380346.

IEEE

A. E. Oxford, E. S. Stewart, and T. T. Rohn, “Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy,” International Journal of Alzheimer s Disease, vol. 2020, pp. 1–13, 2020, doi: 10.1155/2020/5380346.

BibTeX

@article{oxford2020clinical,
  title     = {{Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy}},
  author    = {Oxford, Alexandra E. and Stewart, Erica S. and Rohn, Troy T.},
  journal   = {International Journal of Alzheimer s Disease},
  year      = {2020},
  volume    = {2020},
  pages     = {1--13},
  doi       = {10.1155/2020/5380346},
  url       = {https://doi.org/10.1155/2020/5380346}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202077
20213434
20223535
20231111
20241414
202599
20261313

Its field-weighted citation impact is 2.40: it has been cited 2.40 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • clinical trials
  • amyloid-beta
  • amyloid hypothesis
  • disease-modifying drugs
  • clinical trial failure
  • amyloid clearance
  • tau pathology

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Oxford, A. E., Stewart, E. S., & Rohn, T. T. (2020). Clinical Trials in Alzheimer’s Disease: A Hurdle in the Path of Remedy. International Journal of Alzheimer s Disease, 2020, 1–13. https://doi.org/10.1155/2020/5380346

How many times has this paper been cited?

123 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at International Journal of Alzheimer s Disease: sign in and open the PDF from this page.

Who wrote this paper?

Alexandra E. Oxford, Erica S. Stewart, Troy T. Rohn.

What is the DOI of this paper?

10.1155/2020/5380346, permanently at https://doi.org/10.1155/2020/5380346. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.